Recent developments include quarterly earnings reports showing fluctuations due to client attrition and interest costs, executive appointments, and record highs in recurring contract value.

• NRC's Q4 2025 earnings declined year-over-year due to high client attrition, resulting in a 27% stock price drop [N3].
• The company reported an all-time high total recurring contract value of $152 million as of March 4, 2026 [S1].
• Q2 2025 earnings rose year-over-year driven by cost control and growth in total recurring contract value [N7].
• Rising interest costs contributed to earnings declines in Q1 and Q3 2025, with Q1 earnings dipping year-over-year but shares rising 13% [N8], and Q3 earnings down year-over-year with stock up 12% [N4].
• Shane Harrison was appointed Executive Vice President and Chief Financial Officer in August 2025 [N6].
• The company has experienced profit retreats in Q3 2025 [N5].
• The CEO, Trent Green, was appointed in June 2025, bringing extensive healthcare industry experience [S1].

NRC Health has demonstrated the ability to grow its total recurring contract value to record levels, indicating strong customer engagement and potential for stable revenue streams. The appointment of experienced healthcare executives to key leadership roles may enhance strategic direction and operational execution. Cost control measures have contributed to earnings improvements in certain quarters, suggesting management's focus on operational efficiency. The company's recurring revenue model provides a foundation for predictable cash flows.

The company has faced high client attrition impacting recent earnings, leading to significant stock price declines. Liquidity ratios indicate current liabilities exceed current assets, which may constrain financial flexibility. Rising interest costs have negatively affected earnings in multiple quarters. The absence of a broad short-term or long-term cash incentive program for executives, except for one, may impact management motivation. Competitive pressures in the healthcare analytics market and client retention challenges pose risks to revenue stability.

NRC Health's moat appears to be based on its specialized healthcare insights and analytics services, supported by recurring contract revenue streams and a leadership team with deep healthcare industry experience. The company's ability to maintain and grow its total recurring contract value suggests a degree of customer reliance on its services. However, recent client attrition and competitive pressures may challenge the sustainability of this moat. The company's governance and executive compensation structures align management incentives with shareholder interests, which may support strategic execution.

• Client Attrition: High client attrition has negatively impacted earnings, as reported in Q4 2025, which may affect revenue stability and growth.
• Liquidity Constraints: The company's current ratio of 0.55 and cash ratio of 0.11 as of December 31, 2025, indicate that current liabilities exceed current assets, posing potential liquidity risks.
• Rising Interest Costs: Increased interest expenses have contributed to earnings declines in recent quarters, affecting profitability.
• Market Competition: Competitive pressures in the healthcare analytics and insights market may challenge NRC's ability to retain and grow its customer base.
• Executive Compensation Structure: Limited adoption of short-term and long-term cash incentive programs for executives may impact management alignment and retention.

• NRC Health, formerly National Research Corporation, is a Delaware corporation headquartered in Lincoln, Nebraska.
• The company is publicly traded on NASDAQ under the ticker NRC.
• As of December 31, 2025, NRC had cash and cash equivalents of $4.139 million and current assets of $20.209 million against current liabilities of $36.62 million, resulting in a current ratio of 0.55 and a cash ratio of 0.11, indicating liquidity constraints.
• The company reported net income of $11.6 million and basic and diluted EPS of $50 per share for the fiscal year ended December 31, 2025.
• NRC's total recurring contract value (TRCV) surpassed $152 million as of March 4, 2026, an all-time high for the company.
• The company experienced high client attrition impacting Q4 2025 earnings, which were down year-over-year, and the stock price fell 27% following this report.
• NRC's Q2 2025 earnings rose year-over-year due to cost control and TRCV growth.
• The company faced rising interest costs impacting earnings in Q1 and Q3 2025, with Q1 earnings dipping year-over-year but shares rising 13%, and Q3 earnings down year-over-year with stock up 12%.
• NRC appointed Shane Harrison as Executive Vice President and Chief Financial Officer in August 2025.
• The company has a board of directors with healthcare and technology industry experience, including CEO Trent Green appointed in June 2025.
• NRC Health's business updates and financial results are regularly disclosed via SEC filings and press releases, with recent earnings transcripts and analyst blogs providing additional context.
• The company has disclosed executive compensation details, including equity awards and severance arrangements.
• Aggregate market value of common stock held by non-affiliates was approximately $194.8 million as of June 30, 2025, with 22,536,696 shares outstanding as of April 24, 2026.
• The company has not adopted a short-term or long-term cash incentive program for most named executive officers in 2025, except for one executive.
• NRC Health's filings include detailed risk factors referencing the 2024 10-K for significant risks.
• The company has disclosed governance and director information in its 10-K/A filing dated April 28, 2026.